Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 27, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 31, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-134631
Filed / recorded
Mar 31, 2026, 8:17 PM UTC
Added to OQRO
Oct 7, 2026, 10:28 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Aldeyra Therapeutics, Inc.
Issuer CIK
1341235
Ticker
ALDX
Reporting person
Todd C Brady
Relationship
Director, Officer
Officer title
President and CEO
Security
Bonus Units
Table
Derivative (Table II)
Transaction date
Mar 27, 2026
Transaction code
A
Shares / units
632,318
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
632,318
Ownership form
Direct
Amendment
No
Footnotes from the filing
The bonus units vest ratably in equal annual installments over a four-year period beginning on March 27, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date.
First buy since 2020Traded Mar 19 · filed 1 day later
An Aldeyra Therapeutics director paid $98K out of pocket for Aldeyra Therapeutics shares. 1 other person at Aldeyra Therapeutics bought some too, in the same month. Shares held went up 56% with this purchase.
The CFO of Aldeyra Therapeutics paid $7.1K out of pocket for Aldeyra Therapeutics shares. 1 other person at Aldeyra Therapeutics bought some too, in the same month. Shares held went up 200% with this purchase.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
